Protocol Reference — Retatrutide

retatrutide

1 mg weekly (Wk 1-4) → 2 mg (Wk 5-8) → 4 mg (Wk 9-12) → 6 mg (Wk 13-16) → 9 mg (Wk 17-20) → 12 mg (Wk 21+) — Continuous — chronic therapy

Most conservative starting dose with refined Phase 3 TRIUMPH steps (including 9 mg) to smooth metabolic adaptation and minimize dysesthesia risk.

retatrutide

2 mg weekly (Wk 1-4) → 4 mg (Wk 5-8) → 8 mg (Wk 9-12) → 12 mg (Wk 13+) — Continuous — faster titration to therapeutic ceiling

Follows the clinical decision algorithm used in specific high-efficacy sub-studies. Omits 6 mg and 9 mg steps. For patients with prior GLP-1 agonist experience and good GI tolerance.

Timing Rules

retatrutidemorning

Once weekly on the same day each week

Morning administration allows monitoring of any acute GI or neurological effects during waking hours. Consistent day-of-week dosing maintains steady-state pharmacokinetics.